Carcinotech is a MedTech company specializing in manufacturing 3D printed living tumors using patient-derived biopsies, primary cells, immune cells, and cancer stem cells. Their advanced technology provides a platform for rapid, ethical, and accurate drug discovery, screening, and pre-clinical testing. They work with global partners, leading pharma companies, surgeons, pathologists, and clinicians to accelerate drug discovery and bring more effective cancer treatments to market. Their vision is to be at the forefront of cancer drug testing and provide personalized medicine testing to each individual suffering from cancer to better their chance of treatment and survival.

Carcinotech is a MedTech company with expertise in manufacturing 3D printed living tumours using patient-derived biopsies, primary cells, immune cells and cancer stem cells. Carcinotech’s advanced models provide a platform for rapid, ethical, sustainable, and accurate drug screening, pre-clinical and personalised medicine testing. Working with global partners, leading pharma companies, surgeons, pathologists, clinicians, and industry-leaders, the goal is to accelerate drug screening and enable delivery of more effective cancer treatments to market. Access to Carcinotech’s robotic and automated manufacturing allows for accelerated production, with models offering high-throughput capabilities. We are a team of like-minded, highly-experienced and determined individuals, all sharing a vision for success. Learn more about our models, get in touch.

Gabriel Investments

Eos Advisory

Alba Equity

UK:CO:CARCINOTECH

Carcinotech

Analysis Not Available